Research and development

News from research

Here you will find recent information on our R&D projects. An overview of our most recent announcements on the progress and results of clinical trials and our latest scientific medical publications are shown here.

Older reports can be found in the archive.

 

Latest news

Solid Tumor Study No. 989 with BT-062 still ongoing

After various inquiries presumable triggered by information in the EU Clinical Trials Register Biotest AG wants to clarify that the Phase I/IIa study with BT-062 in the indications triple negative metastatic breast cancer and metastatic bladder cancer is still ongoing. ... [More]

Biotest Phase IIb study of Tregalizumab (BT-061) in mod...

24.04.2015,

Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Biotest Phase IIb study of Tregalizumab (BT-061) in moderate to severe rheumatoide Arthritis did not meet the primary endpoint - p ... [More]

Monoclonal antibody BT-061 shows efficacy in the indica...

17.03.2010,

Monoclonal antibody BT-061 shows efficacy in the indication psoriasis  Final results of Phase I/IIa trial in chronic plaque psoriasis show long- lasting therapeutic effect after a single adminis ... [More]

Biotest: Promising start of clinical trial with BT062

22.09.2008,

Biotest: Promising start of clinical trial with BT062 - Monoclonal antibody was generally well tolerated at the first dose level - Clinical study in indication multiple myeloma can proceed as plann ... [More]

Biotest: monoclonal antibody BT-061 shows clear indicat...

08.09.2008,

Biotest: monoclonal antibody BT-061 shows clear indications of efficacy in the treatment of Psoriasis - First analysis of clinical Phase I/IIa trial - Clear improvement of symptoms already at low d ... [More]

Biotest awarded patent protection in the USA

29.07.2008,

Biotest awarded patent protection in the USA · Patent prosecution for BT-061 successfully completed by US authorities · Decision confirms innovative character of the monoclonal antibody · Compreh ... [More]

research into additional indications for monoclonal ant...

05.05.2008,

Biotest: research into additional indications for monoclonal antibody BT-061 - Research cooperation agreed with the University of Mainz for BT-061 - Biotest’s industrial property rights extended ... [More]

European approvals expand the market potential for plas...

14.04.2008,

Biotest: European approvals expand the market potential for plasma proteins · Factor VIII product Haemoctin® and immunoglobulin Hepatect® approved for use in additional countries · Synergies gen ... [More]

Biotest achieves major milestones in the development of...

11.03.2008,

Biotest achieves major milestones in the development of biotherapeutics · Orphan drug designation granted for monoclonal antibody, BT-062, in the USA · Up to seven years’ market exclusivity from ... [More]

Biotest achieves further milestones in its monoclonal a...

25.06.2007,

Biotest achieves further milestones in its monoclonal antibody development · Phase I clinical trial confirms good tolerability profile of BT-061. · Start of production for the clinical testing of ... [More]